Medlive Technology Co., Ltd.

SEHK:2192 Stock Report

Market Cap: HK$5.3b

Medlive Technology Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Liping Tian

Chief executive officer

CN¥7.2m

Total compensation

CEO salary percentage22.0%
CEO tenure11yrs
CEO ownership0.8%
Management average tenureno data
Board average tenure5.8yrs

Recent management updates

Recent updates

Medlive Technology Co., Ltd.'s (HKG:2192) Business Is Yet to Catch Up With Its Share Price

Apr 08
Medlive Technology Co., Ltd.'s (HKG:2192) Business Is Yet to Catch Up With Its Share Price

Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Feb 20
Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?

Jan 10
Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?

Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price

Sep 27
Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price

Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Jul 10
Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless

May 11
Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless

Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)

May 02
Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)

Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 26
Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital

Feb 06
Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital

There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital

Oct 31
There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital

Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Jul 14
Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts

Apr 03
These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts

Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?

Feb 22
Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?

CEO Compensation Analysis

How has Liping Tian's remuneration changed compared to Medlive Technology's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

CN¥242m

Sep 30 2023n/an/a

CN¥216m

Jun 30 2023n/an/a

CN¥189m

Mar 31 2023n/an/a

CN¥153m

Dec 31 2022CN¥7mCN¥2m

CN¥117m

Sep 30 2022n/an/a

CN¥83m

Jun 30 2022n/an/a

CN¥48m

Mar 31 2022n/an/a

CN¥44m

Dec 31 2021CN¥7mCN¥1m

CN¥41m

Sep 30 2021n/an/a

CN¥55m

Jun 30 2021n/an/a

CN¥70m

Mar 31 2021n/an/a

CN¥78m

Dec 31 2020CN¥816kCN¥816k

CN¥85m

Dec 31 2019CN¥756kCN¥756k

CN¥31m

Dec 31 2018CN¥736kCN¥736k

CN¥14m

Compensation vs Market: Liping's total compensation ($USD1.00M) is above average for companies of similar size in the Hong Kong market ($USD517.52K).

Compensation vs Earnings: Liping's compensation has been consistent with company performance over the past year.


CEO

Liping Tian (56 yo)

11yrs

Tenure

CN¥7,249,000

Compensation

Ms. Liping Tian is Chairwoman and Chief Executive Officer of Medlive Technology Co. Ltd. Ms. Tian has been Executive Director of Medlive Technology Co. Ltd since April 2013. She has been the executive dire...


Board Members

NamePositionTenureCompensationOwnership
Liping Tian
Chairwoman & CEO11yrsCN¥7.25m0.75%
CN¥ 40.1m
Lixin Tian
President10.3yrsCN¥2.64m0.18%
CN¥ 9.7m
Lijun Tian
VP, Deputy Head of Medical Information Science Research Unit & Executive Director10.3yrsCN¥2.58m0.13%
CN¥ 6.8m
Xin Zhou
VP & Executive Director5.8yrsCN¥579.00kno data
Richard L. Yeh
Independent Non-Executive Director3.3yrsCN¥109.00kno data
Eiji Tsuchiya
Non-Executive Director10.3yrsno datano data
Jun Ma
Independent Non-Executive Director3.3yrsCN¥109.00kno data
Shan Wang
Independent Non-Executive Director3.3yrsCN¥109.00kno data
Kazutaka Kanairo
Non-Executive Directorless than a yearno datano data

5.8yrs

Average Tenure

54yo

Average Age

Experienced Board: 2192's board of directors are considered experienced (5.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.